Primary sarcomatoid lung cancer: clinical and evolutive features:About five case reports.

##plugins.themes.academic_pro.article.sidebar##

Published Feb 26, 2015
Download
pdf
Vol. 92 No. 11 (2014): Issue Nov 2014

##plugins.themes.academic_pro.article.main##

Inès Zendah
Sonia Habibech
Hamida Kwas
Aida Ayadi
Amel Khattab
Asma Zidi
Habib Ghédira

Abstract

Background: Primary sarcomatoid carcinoma of the lung are rare non small cell lung cancers (NSCLC) recently individualized by the World Health Organization. Their clinical, radiological and evolutive features are not well known but they seem to have bad prognosis with rapid progression and early metastases. Although they are felt to be chemo-refractory they must be treated as the other subtypes of NSCLC.

Aim: To evaluate clinical, radiological and evolutive features of primary sarcomatoid carcinoma of the lung.

Methods: We report the cases of five patients presenting sarcomatoid carcinomas and assess their clinical and evolutive data.

Results: One patient had stage IIB cancer underwent surgical resection and adjuvant chemotherapy, he is alive 18 months later; another had stage IIIB was treated by radio and chemotherapy and is alive 6 months later; and three other patients had stage IV in whom one had chemotherapy, the two others did not because of they had performance status. They died 1 to 3 months after the diagnosis.

Conclusion: Lung sarcomatoid carcinomas are of bad prognosis. Their treatment is nowadays not well established. Much more good studies are therefore needed.

Keywords:

Adjuvant chemotherapy, Ileal metastases, Non small cell lung cancer, Sarcomatoid carcinoma, Surgical resection.

##plugins.themes.academic_pro.article.details##

References

  1. Fishback NF, Travis WD, Moran CA, Guinee DG Jr, McCarthy WF, Koss MN. Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer. 1994; 73:2936-45.
  2. Rossi G et al. Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. Am. J. Surg. Pathol. 2003; 27: 311-324.
  3. Pelosi G et al. Pulmonary sarcomatoid carcinomas: a practical overview. Int. J. Surg. Pathol. 2010; 18:103-20.
  4. Raveglia F et al. Personal experience in surgical management of pulmonary pleomorphic carcinoma. Ann Thorac Surg. 2004; 78:1742-7.
  5. Davis MP, Eagan RT, Weiland LH, Pairolero PC. Carcinosarcoma of the lung: Mayo Clinic experience and response to chemotherapy. Mayo Clin Proc. 1984; 59: 598-603.
  6. Nakajima M, Kasai T, Hashimoto H, Iwata Y, Manabe H. Sarcomatoid carcinoma of the lung: a clinicopathologic study of 37 cases. Cancer. 1999; 86: 608- 16
  7. Ro JY, Chen JL, Lee JS, Sahin AA, Ordonez NG, Ayala AG. Sarcomatoid carcinoma of the lung. Immunohistochemical and ultrastructural studies of 14 cases. Cancer 1992; 69: 376-86
  8. Italiano A et al. EGFR and KRAS status of primary sarcomatoid carcinoma of the lung: Implications for anti EGFR treatment of a rare lung malignancy. Int J Cancer. 2009; 125: 2479-2482.
  9. Leone A et al. Identification of EGFR mutations in lung sarcomatoid carcinoma. Int J Cancer. 2011; 128: 732-735
  10. Jamie E et al. Clinical outcomes with preoperative chemotherapy in sarcomatoid carcinoma of the lung. J Thorac Oncol. 2012; 7: 1400-05
  11. Schultheis B, Kummer G, Strumberg D. Sarcomatoid non small cell lung cancer responding to suntinib. Int J Clin pharmacol ther. 2013; 51: 87-88
  12. Yendamuri S et al. Outcomes of sarcomatoid carcinoma of the lung: A surveillance, epidemiology and results database analysis. Surgery. 2012; 125: 397-402.
  13. Martin LW et al. Sarcomatoid carcinoma of the lung: a predictor of poor prognosis. Ann Thorac Surg. 2007; 84: 973-80
  14. Moon KC et al. Expression of caveolin-1 in pleomorphic carcinoma of the lung is correlated with a poor prognosis. Anticancer Res. 2005; 25: 4631-7.